In a 29-year-old woman taking the weight‑loss medication Reta (generic name unknown) who has had two weeks of intermittent palpitations, cold intolerance, fatigue, non‑orthostatic dizziness, and multiple near‑syncope episodes, what is the appropriate evaluation and management?

Immediate Discontinuation of Reta and Urgent Cardiovascular Evaluation Required

This patient requires immediate discontinuation of Reta (retatrutide) and urgent cardiovascular assessment for suspected cardiac arrhythmia, given the constellation of near-syncope episodes, palpitations, and cold intolerance in the setting of a weight-loss medication known to cause dose-dependent tachycardia. 1

Critical Drug-Related Concerns

The FDA labeling for Reta explicitly warns that retatrutide causes dose-dependent increases in heart rate that peak at 24 weeks 2. Your patient is taking this medication and presenting with:

• Multiple near-syncope episodes (high-risk feature)
• Palpitations (arrhythmia symptom)
• Non-orthostatic dizziness
• Cold intolerance (possible thyroid dysfunction or autonomic dysregulation)

Stop Reta immediately 1. The drug label specifically contraindicates use in patients with recurrent hypoglycemia or conditions predisposing to hemodynamic instability, and near-syncope represents significant hemodynamic compromise.

Urgent Cardiovascular Workup Algorithm

Step 1: Immediate ECG and Risk Stratification

Obtain a 12-lead ECG immediately to evaluate for:

• QT prolongation (drug-induced or congenital long QT syndrome)
• Pre-excitation patterns (WPW syndrome)
• Conduction abnormalities (AV block, bundle branch block)
• Ventricular ectopy or nonsustained ventricular tachycardia
• Signs of structural heart disease 3, 4, 5

Any ECG abnormality or suspicion of inherited cardiac condition mandates urgent specialist referral 6, 3.

Step 2: Ambulatory Cardiac Monitoring

Given multiple near-syncope episodes over 2 weeks with intermittent palpitations, this patient requires rhythm documentation during symptoms 6, 7:

• If symptoms occur daily: 24-48 hour Holter monitor
• If symptoms occur weekly (your patient's pattern): External loop recorder or patch recorder for 2-4 weeks 7
• If ECG shows any abnormality: Consider immediate inpatient telemetry 7

The goal is ECG documentation during a symptomatic episode to establish arrhythmic causation 5.

Step 3: Echocardiography

Obtain transthoracic echocardiogram to exclude:

• Structural heart disease (valvular disease, cardiomyopathy)
• Left ventricular dysfunction
• Hypertrophic cardiomyopathy (common cause of sudden death in young adults) 5, 7

This is particularly important given her age and the severity of symptoms (near-syncope) 3.

Step 4: Orthostatic Vital Signs

Measure blood pressure and heart rate supine and after 3 minutes of standing to evaluate for:

• Classical orthostatic hypotension (BP drop ≥20/10 mmHg)
• Postural orthostatic tachycardia syndrome (POTS): HR increase >30 bpm 8
• Delayed orthostatic hypotension (progressive BP decline over several minutes)

However, she reports non-orthostatic dizziness, making pure autonomic dysfunction less likely but still requiring exclusion 8.

Differential Diagnosis Priority

Most Likely (Given Clinical Context):

1. Drug-induced tachyarrhythmia from retatrutide 1, 2
2. Supraventricular tachycardia (AVNRT, AVRT) - paroxysmal nature fits 3
3. Inappropriate sinus tachycardia - can cause similar symptoms 9, 10

Must Exclude (High Mortality Risk):

1. Ventricular arrhythmias - near-syncope is high-risk feature 4
2. Long QT syndrome - can be drug-induced or congenital 5
3. Structural heart disease with arrhythmia substrate 3

Consider:

1. Thyroid dysfunction - cold intolerance suggests hypothyroidism, but can also occur with hyperthyroidism causing tachyarrhythmias
2. Autonomic dysfunction/POTS - though less likely given non-orthostatic nature 8, 9

Management Algorithm

Immediate actions:

1. Stop Reta permanently 1
2. 12-lead ECG today
3. Orthostatic vital signs
4. Thyroid function tests (TSH, free T4)

Within 48-72 hours:

1. Echocardiogram
2. Initiate ambulatory monitoring (external loop recorder for 2-4 weeks)
3. Consider basic metabolic panel, CBC, magnesium

Specialist referral criteria 3:

• Urgent cardiology/electrophysiology referral if:
  • Any ECG abnormality suggesting arrhythmia risk
  • Structural heart disease on echo
  • Documented arrhythmia on monitoring
  • Recurrent near-syncope despite Reta discontinuation

Critical Pitfalls to Avoid

1. Do not attribute symptoms to "stress" or "anxiety" without excluding cardiac causes - multiple near-syncope episodes in a young patient warrant thorough evaluation 3, 10

2. Do not rely on the "normal" cardiac workup from 6 months ago - she is now on a cardioactive medication and has new, high-risk symptoms 4

3. Do not perform tilt-table testing as first-line investigation - this is reserved for suspected vasovagal syncope after cardiac causes are excluded 6, 7

4. Do not miss drug-induced QT prolongation - weight loss medications purchased online have caused torsades de pointes and cardiac arrest 11

5. Do not restart Reta - even if workup is negative, the temporal relationship between medication use and symptoms is concerning 1

Expected Clinical Course

If symptoms are purely drug-related, expect improvement within 1-2 weeks after Reta discontinuation as the medication clears (heart rate increases peaked at 24 weeks and declined thereafter in trials) 2. If symptoms persist beyond 2 weeks off medication, this suggests an underlying primary cardiac arrhythmia that requires definitive treatment 3, 7.

The combination of near-syncope (not just presyncope) with palpitations in a young patient taking a medication known to increase heart rate creates significant risk for sudden cardiac death if an arrhythmia is present 4. Aggressive evaluation is warranted and potentially life-saving 6, 3.